Navigation Links
Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New,Treatment Benchmark in Patients With Metastatic Colorectal Cancer

of all the results reported. In comparison, the chance of living five years was 5.4% among patients treated with Eloxatin(R) plus irinotecan (IROX) (p=.016) and 3.8% (p<.001) among patients treated with the combination of 5-FU/LV and irinotecan (IFL).

FOLFOX4 slowed the progression of the disease compared to IROX and IFL. The median TTP was significantly longer among FOLFOX4-treated patients at 9.2 months compared to 6.5 months with IROX (p=<.001) and 6 months with IFL (p=<.001). FOLFOX4 patients were significantly more likely to experience any grade 3 or greater side effects (odds ratio of 1.65, p<.001) and were lower in men than in women (OR 0.63, p<0.001). The most common side effects were peripheral sensory neuropathy, fatigue, neutropenia, nausea, vomiting, and diarrhea.

"Our five-year overall survival results with first-line FOLFOX4 set a new benchmark for treating metastatic colorectal cancer," said lead investigator Richard Goldberg, MD, University of North Carolina School of Medicine, Chapel Hill, NC. "Adding Eloxatin(R) to standard chemotherapy significantly prolonged survival for these patients and also delayed disease progression."

Treatment with FOLFOX4 Predicts Important Benefits

Receiving FOLFOX4 was found to be the most powerful prognostic factor for predicting overall survival as well as time to progression. Those factors that were predictive of a worse outcome were: higher baseline performance status, neutrophil count, and alkaline phosphatase, as well as a greater number of disease sites. While being 70 years or older was associated with poorer survival, it was not predictive of time to progression, response rate or grade 3 or greater toxicity.

For more information about Eloxatin(R) or for full prescribing information, including BOXED WARNING, visit www.eloxatin.com.

About Colorectal Cancer

Strides have been made in the management of colorectal
'"/>




Page: 1 2 3 4

Related medicine technology :

1. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
2. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
3. July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of Factive Tablets for Five-Day Treatment of Community-Acquired Pneumonia
4. New Data Show Pfizers Axitinib Prolonged Overall Survival in Advanced Pancreatic Cancer When Combined with Standard of Care Chemotherapy
5. Hyperthermia Plus Chemotherapy Nearly Doubles Disease-Free Survival Compared to Chemotherapy Alone for Sarcoma Cancer Patients
6. Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
7. MabThera Significantly Extends Survival And Cures More Patients With Aggressive Lymphoma Than Chemotherapy Alone
8. Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy
9. MabThera Significantly Increases Survival of Lymphoma Patients Regardless of Chemotherapy Regimen
10. Abraxis BioScience Presents Data from Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining nab-Paclitaxel (Abraxane) with Anti-Angiogenic Agents to Increase Tumor Response
11. Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual Meeting

Post Your Comments:
(Date:11/27/2009)..., BLOOMINGTON, Minn, Nov. 27 ACUO...cal image management software, data migration tool...ited States Patent and Trademark Office has approv...n Format within a Computer Network." Acuo Technolo...folio of intellectual property. In general, the gr...
(Date:11/25/2009)... , CANOGA PARK, Calif., Nov. 25 ...place rankings in the American Academy of Family P... 2009 EHR User Satisfaction Survey for improving m...nagement, all critical for new ARRA Stimulus legis...ting their EMR had a positive effect in determinin...
(Date:11/25/2009)... , BEDFORD, Mass., Nov. 25 /PRNewswire-FirstCa...daq: HOLX ), a leading developer, manufacturer an... systems and surgical products dedicated to servin...al meeting of the Radiological Society of North Am...er 29 through December 3, 2009 to highlight our ne...
Breaking Medicine Technology:Acuo Technologies Announces Patent for Asset Communication Format Within a Computer Network 2Praxis EMR Wins Top Rankings in 2009 AAFP EHR User Satisfaction Survey 2New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 2New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 3New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 4Lupus Research Institute announces 2009 novel research grants 10894 1Lupus Research Institute announces 2009 novel research grants 10894 2Lupus Research Institute announces 2009 novel research grants 10894 3Springer and the American College of Medical Toxicology to work together 10889 1Springer and the American College of Medical Toxicology to work together 10889 2Cholesterol Plays Role in Heart Failure Risk 62037 1Cholesterol Plays Role in Heart Failure Risk 62037 2
... VIENNA, Austria, June 11 /PRNewswire-FirstCall/,-...ed the publication of data,from the company,s posi...ea,vaccine in The Lancet. The study, which analyze...eived the Iomai patch-based vaccine were,statistic...ically,significant diarrhea than their counterpart...
...ter Presentation at the Associated Professional Sl...ing, BALTIMORE, June 11 Data was presented today...essional Sleep Societies (APSS),demonstrating that...), an,investigational low-dose, sublingual formula...y that was significantly greater than that produce...
Other Medicine Technology:Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers' Diarrhea Vaccine 2Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers' Diarrhea Vaccine 3Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers' Diarrhea Vaccine 4Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers' Diarrhea Vaccine 5Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers' Diarrhea Vaccine 6Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers' Diarrhea Vaccine 7Intermezzo(R) 3.5 mg Achieves Greater Early Bioavailability Than Ambien(R) 10 mg Despite 65% Lower Dose 2Intermezzo(R) 3.5 mg Achieves Greater Early Bioavailability Than Ambien(R) 10 mg Despite 65% Lower Dose 3Intermezzo(R) 3.5 mg Achieves Greater Early Bioavailability Than Ambien(R) 10 mg Despite 65% Lower Dose 4Intermezzo(R) 3.5 mg Achieves Greater Early Bioavailability Than Ambien(R) 10 mg Despite 65% Lower Dose 5
(Date:11/26/2009)..., PRINCETON, N.J., Nov. 27 The di... double over the next 25 years and annual medical ...illion, up from $113 billion today, according to a...s Care . The National Changing Diabetes ® P...oned the analysis by a team from the University of...
(Date:11/26/2009)...t,s too big or too heavy can lead to strains or wo...s) -- There may be nothing wrong with stuffing you...to do the same thing with your suitcase as you pac...were treated in 2008 in U.S. hospital emergency ro...acilities for luggage-related injuries, such as mu...
(Date:11/26/2009)... Dr. David Kim of the Live Life Agai... in Dallas , is one of a growing number of physici...tworking sites to connect with individuals who are...ight morbid obesity. Dr. Kim is utilizing Facebook...about his practice with the community. , ...
(Date:11/26/2009)... Ennis & Ennis, P.A. is offering...ers of Yaz and Yasmin birth control pills who have...Embolism, Stroke, Heart Attack or other related ca...en can call toll free at 1-800-856-6405 or go to t...m and fill out an online case evaluation form. ,...
(Date:11/25/2009)..., EMERYVILLE, Calif., Nov. 25 /PRNewswire-FirstCa... ) today announced that the company will host two ... ,, December 7, 2009 - 9:00 a.m. CT/10:00 a...s data presentations surrounding carfilzomib in re...ured at the 51st American Society of Hematology (A...
Breaking Medicine News(10 mins):Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 4Health News:Pack Right for the Holidays to Avoid the ER 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 3Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 3Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2
...ican College of Allergy,Asthma & Immunology (ACAAI...merica surveys that highlight the importance of im...These survey findings and other important,informat...driving the dialogue about unmet needs for patient...
... 22 Medco Health,Solutions, Inc., (NYSE: MHS ) t...dHealth Group to provide pharmacy benefit services...ext generation of collaboration with,UnitedHealth ...p and includes new terms that provide clear alignm...
... To enhance absorption, the,Longevinex(R) matrix ...resveratrol, microencapsulated in an envelope of a... resveratrol in its trans-resveratrol form,from de...resveratrol matrix withstands direct,exposure to s...
...ERTIFICATION PROGRAM CONTINUES TO EXPAND IN THE ... April 22 More people than ever,before are buying...,standards -- especially people with asthma and al...ts and finishes from manufacturing or,packaging, a...
...onal Union files anti-SLAPP motion against,the Cal... vacate TRO,publicity stunt, OAKLAND, Calif., Apr...SEIU) today filed an anti-Strategic Lawsuit,to Pre...ivisive tactics. The motion cites a temporary rest...
...Jury Endorses Competition in the Durable Medical ...TTLE, April 21 Seattle law firm Williams Kastner,...ay in a business,litigation case involving claims ...man, Warren and Ruth Ann Hall and Halls,Drug Cente...
Other Medicine News:Health News:Medco, UnitedHealth Group Announce Pharmacy Services Agreement 2Health News:New: Longevinex(R) First to Introduce Micronized Resveratrol Matrix - Now Stabilized by Microencapsulation 2Health News:More Americans are Sleeping Thanks to Science 2Health News:SEIU Seeks Damages for CNA's Effort to Silence Workers, Suppress Criticism of Anti-Union Tactics 2Health News:SEIU Seeks Damages for CNA's Effort to Silence Workers, Suppress Criticism of Anti-Union Tactics 3Health News:SEIU Seeks Damages for CNA's Effort to Silence Workers, Suppress Criticism of Anti-Union Tactics 4
...ble, light weight, high power Erbium:YAG laser sys... plastic surgery, general surgery, ENT and ophthal... the smallest, yet among the most powerful, Erbium...eatment for younger patients with mild wrinkles or...
...d to induce interstitial laser coagulation or tiss...en used to induce interstitial laser coagulation, ...rgy to heat the targeted tissue to a temperature r...ow temperatures at which carbonization begins. Whe...
...ghly accurate measurements of intraocular pressure...ic for the diagnosis and treatment of glaucoma. H...-year National Institute of Health (NIH) study pub...ickness (CCT) is an important and necessary biomet...
Gonorrhea Swabs
Medicine Products: